Sep 27, 2022 / 12:00PM GMT
Operator
Good day, and welcome to the EPIPHAST II update call. (Operator Instructions). As a reminder, this call may be recorded.
I would now like to turn the call over to Dan Barber, CEO of Aquestive Therapeutics. You may begin.
Daniel Barber - Aquestive Therapeutics, Inc. - CEO, President & Director
Thank you, operator, and good morning, everyone. Thank you for joining the call today. We appreciate your time and continued engagement.
Before I begin, you will see that we have included our company cautionary forward-looking statements made under the Safe Harbor provisions of securities laws on Slide 2 of our presentation. As a reminder, information included in this presentation is based on the company's review and evaluation of the clinical data regarding AQST-109. All conclusions and determinations contained in this presentation are subject to the company's further analysis of the clinical data. The ultimate determination of the safety and efficacy of AQST-109 will be made by the FDA. We ask that you keep these cautionary statements in mind when
Aquestive Therapeutics Inc Announces Positive EPIPHAST II Trial Data for AQST-109 When Compared to EpiPen Call Transcript
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot